Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Coronary diseaseAcute coronary syndromesMedtronic educational sessions

Latin Program for the Treatment of STEMI

solaci
solaci
626
0

Latin Program for the Treatment of STEMI.

Presenters:

Dr. Marco Alcocer, México.
Dr. Marcus Lacativa, Brasil.
Dr. Humberto Casal, Venezuela.

This video, sponsored and funded by Medtronic, was filmed during SOLACI-CACI 2017 Congress, at Hilton Buenos Aires Hotel (in Argentina).

Do you want to take a look at all other SOLACI-CACI 2017 Congress Medtronic cases?
Watch them 

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
Percutaneous Interventions After TAVR
Next article
DES XL for Left Main Coronary Artery Lesions
solaci
solaci

More articles by this author

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

Dr. Juan Manuel Pérez - 0
The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Dr. Juan Manuel Pérez - 0
Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...

EuroPCR 2026 | Is localized anticoagulation the next step for coronary stents?

Dr. Juan Manuel Pérez - 0
The DESyne BDS Plus stent was developed as a thin-strut, bioabsorbable polymer drug-eluting stent that combines sirolimus release with two anticoagulant agents (rivaroxaban and...

EuroPCR 2026 | Restoring vascular physiology: 4-year results of the BIOADAPTOR-RCT

Dr. Juan Manuel Pérez - 0
Despite advances in drug-eluting stents, device-related events continue to increase beyond the first year after angioplasty. In this context, the DynamX system emerged as...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Coronary disease

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However,...
Dr. Juan Manuel Pérez -
SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

Dr. Andrés Rodríguez - 0
This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

Dr. Juan Manuel Pérez - 0
The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Dr. Juan Manuel Pérez - 0
Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...